Yichen Guo, Ph.D.

Yichen Guo, Ph.D. has worked in various scientific roles since 2011. From 2011 to 2018, they worked as an Associate Scientist in Immuno-oncology at Nanjing University of Traditional Chinese Medicine, where they developed single-chain antibody to target HER-2+ breast cancer. From 2017 to 2018, they were a Graduate Research Assistant (PhD Candidate-PhD) at UAB Medicine, where they were a scientific leader with expertise in tumor microenvironment relevant to the interaction between cancer stem cell and tumor-associated endothelial cell by microflow device technique. Yichen also had the ability to deepen scientific understanding of CD36-mediated fatty acid metabolism regulation of stemness features, which contribute to therapeutic resistance and metastasis in cancers. From 2015 to 2017, they were an Undergraduate Research Assistant at The University of Alabama, where they had expertise in a variety of fermentation strategies and worked on high production of biochemical and/or biofuel using clostridia. From 2017 to 2018, they were a Researcher II in Anti-Cancer Biopharmaceuticals Development at University of Alabama at Birmingham, where they designed and constructed chimeric receptor plasmid and generated lentivirus to transfect T cells and worked independently to synthesize and produce ScFv attached plasmid and expressed and purified protein of ScFv. From 2017 to 2018, they were a Technical Paraprofessional at Augusta University. Yichen currently works as a Scientist in Antibody and Assay at OriGene, where they design, develops, and generates new antibodies for diagnostic and therapeutic purposes and designs, develops, and optimizes quantitative in vitro assay, such as ELISA, Luminex, etc. for biological functional assay.

Yichen Guo, Ph.D. earned a Doctor of Philosophy in Biomedical/Medical Engineering from the University of Alabama at Birmingham in 2022. Prior to this, they attended The University of Alabama from 2012 to 2016, studying Chemical Engineering.